Please assess the completion status of the following clinical trial:

Trial Title: A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Mild to moderate essential hypertension : sitting diastolic blood pressure measured at Placebo visit and Baseline are 90\~109mmHg inclusive and the difference between sitting diastolic blood pressures measured at Placebo visit and Baseline(Day0) is under 7mmHg.~* Subjects who agree to participate in this sudy and give written informed consent~* Subjects considered to understand the study, be cooperative, and able to be followed-up until the end of the study~Exclusion Criteria:~* The sitting DBP is less than 89mmHg or more than 110mmHg or severe hypertensive patient with sitting systolic blood pressure over 200mmHg Patients with secondary hypertension~* Patients with severe renal(Creatinine more 1.5mg/dl), gastrointestinal, hematological or hepatic(AST, ALT more 2 twice more than upper limit of normal)disease etc. which might affect absorption, disposition, metabolism or excretion of the drug~* Patients with postural hypotension~* Patients with sever insulin dependent diabetes mellitus or uncontrolled diabetes mellitus(HbA1c\>9%, regimen change of oral hypoglycemic agents within 12weeks, treated insulin before screening)~* Patients with a history of myocardial infarction, severe coronary artery disease or clinically significant heart failure or valvular defect in last 6 months~* Patients with consumptive disease, autoimmune disease, connective tissue disease~* Patients with a history of type B or C hepatitis~* Patients with HIV or hepatitis~* Patients with clinically significant laboratory abnormality~* Patients receiving any drugs known to affect blood pressure or medical treatments that can influence the blood pressure~* Patients with allergy or contraindication to any angiotensin II receptor antagonists~* Female of childbearing potential who does not undergo hysterectomy or is not post-menopausal~* Patients judged to have a history of alcohol or drug abuse by the investigator~* Patients participated other clinical trial 12 weeks before Screening Patients judged to be inappropriate for this study by the investigator with other reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fimasartan 1 (Type: EXPERIMENTAL): Fimasartan 60 mg group
- Fimasartan 2 (Type: EXPERIMENTAL): Fimasartan 120 mg group
- Valsartan (Type: ACTIVE_COMPARATOR): Reference (Valsartan 80 mg) group

Based on this trial design, predict the completion outcome and termination type (if applicable).